ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0935

Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy

Giorgio CASABURI, Tyler O'Malley, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Bioinformatics, clinical trial, Gene Expression, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity. RA affects approximately 0.5/1% of adults in the United States. Currently, conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) are the first line therapy for RA. However, about 40% of patients do not respond to csDMARDs and will require subsequent biological therapy. The identification at disease onset of patients who are likely to respond to csDMARDs remains a major unmet need, adding millions of dollars in medical expenses to the US healthcare system annually, as well as negatively impacting overall patients’ life. Here, we present a new generation of machine learning algorithms that can accurately identify RA treatment-naïve patients likely to respond to csDMARDs, informing initial RA treatment selection to maximize the potential of csDMARDs and promote early biologic intervention where appropriate.

Methods: A minimum of six synovial biopsies samples per patient were collected from 95 patients at baseline, followed by bulk RNA sequencing. Outcome data was collected at 3 months to classify patients who needed to switch to biological therapy and used for model training. After quality filtering, RNA-Seq annotation, and normalization, the resulting dataset went through an automated machine learning pipeline, capable of concurrently running hundreds of different cross-validated models. Models were trained to predict patients that would respond to csDMARDs. Feature selection and reduction techniques were applied to reduce the number of required predictive biomarkers, while maintaining elevated accuracy. A multi-fold generalizability test was performed on the final set of biomarkers by means of permutational hold out (HO) predictions, e.g., the portion of data that is always blind during training and validation modeling.

Results: A set of unique biomarkers were identified to be highly predictive in discriminating patients that responded or not to csDMARDs at 3 months after sample collection. The average area under the curve (AUC) for the blind HO portion of data was 0.85, with a sensitivity of 0.92 and a specificity of 0.69. Patient probabilities distributions derived from selected biomarkers showed a net separation of responder vs non-responder patients to csDMARDs.

Conclusion: The ability to identify the most appropriate treatment for early RA patients by targeted sequencing in the synovium offers a new opportunity to personalize therapeutic interventions to the patients most in need. This study reinforces the need to change current therapeutic procedures with the help of AI and Big Data to predict during therapeutical decisions the need of biological therapies at disease onset. This approach is likely to have a major impact on disease control, remission, overall healthcare cost, and especially patients’ quality of life.


Disclosures: G. CASABURI, Exagen Inc.; T. O'Malley, Exagen; T. Holscher, Exagen Inc.; M. Lee, None.

To cite this abstract in AMA style:

CASABURI G, O'Malley T, Holscher T, Lee M. Targeted Synovial Tissue RNA-Seq Coupled with Artificial Intelligence Accurately Predicts Early Rheumatoid Arthritis Patients Likely to Respond to CsDMARDs, Enriching CsDMARDs Response Rates and Enabling Early Identification of Patients Requiring Subsequent Biological Therapy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/targeted-synovial-tissue-rna-seq-coupled-with-artificial-intelligence-accurately-predicts-early-rheumatoid-arthritis-patients-likely-to-respond-to-csdmards-enriching-csdmards-response-rates-and-enabl/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeted-synovial-tissue-rna-seq-coupled-with-artificial-intelligence-accurately-predicts-early-rheumatoid-arthritis-patients-likely-to-respond-to-csdmards-enriching-csdmards-response-rates-and-enabl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology